Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]

  • In development
  • GID-TA11488
  • Expected publication date: TBC

NIHRIO BN: 30956-Tafasitamab-Lenalidomide-for-Follicular-or-Marginal-Zone-Lymphoma-V1.0-NOV2023-NON-CONF.pdf (nihr.ac.uk)